| Name | Title | Contact Details |
|---|
Pherin Pharmaceuticals Inc is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.
Medicine Hat Office is a Medicine Hat, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three pillars that shape our company. First, we are driven by impactful science. Second, we accept no middle ground when it comes to product quality. Finally, we believe in fostering a career of craftsmanship, where our people can become experts in their trade. The spirit of our culture is to work hard, and be nice to people.
We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.